Inside Amylyx's headquarters in Cambridge, MA (courtesy Amylyx/Kathy Wong for Endpoints News)
Fresh off ALS drug withdrawal, Amylyx touts interim rare disease data for the same therapy
A week after voluntarily pulling its ALS drug off the market following a failed Phase 3 trial, Amylyx Pharmaceuticals …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
